 |  |  |  |  |  |
| Copyright 2006-2010 Abiant, Inc. |
| Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030 |
| New and Events... |
Abiant News
Abiant Selected to Present at 2009 Human Amyloid Imaging Conference
Deerfield, ILLINOIS - - April 24, 2009 - - Work co-authored by members of Abiant and the New York
University School of Medicine was presented on April 24 at the 2009 Human Amyloid Imaging (HAI)
Meeting in Seattle, Washington. The presentation, titled "Combining Amyloid Imaging and
Measurement of Regional Cerebral Glucose Metabolism to Evaluate Dementia State and
Progression", focused on the results of analyses performed using two different types of imaging
scans on participants in the Alzheimers Disease Neuroimaging Initiative (ADNI).
A copy of the abstract is available by clicking here: HAI 2009 Abstract.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Further information from the HAI Meeting can be found at HAI Meeting Notes provided by the
Alzheimers Forum.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Deerfield, ILLINOIS - - April 24, 2009 - - Work co-authored by members of Abiant and the New York
University School of Medicine was presented on April 24 at the 2009 Human Amyloid Imaging (HAI)
Meeting in Seattle, Washington. The presentation, titled "Combining Amyloid Imaging and
Measurement of Regional Cerebral Glucose Metabolism to Evaluate Dementia State and
Progression", focused on the results of analyses performed using two different types of imaging
scans on participants in the Alzheimers Disease Neuroimaging Initiative (ADNI).
A copy of the abstract is available by clicking here: HAI 2009 Abstract.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Further information from the HAI Meeting can be found at HAI Meeting Notes provided by the
Alzheimers Forum.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
 |
 |